SRC kinase inhibitor compounds

US6316444A · kind A · utility

Assignee

• MERCK & CO., INC. · US

Inventors

• Julianne A. Hunt · Scotch Plains, US
• Sander G. Mills · Scotch Plains, US
• Peter J. Sinclair · Highland Park, US
• Dennis Zaller · Scotch Plains, US

Key dates

• Filing date: Jun 26, 2000
• Grant date: Nov 13, 2001
• Expiry date: Jun 26, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.